A retrospective multicenter evaluation of clozapine use in pediatric patients admitted for acute psychiatric hospitalization

Laura M. Steinauer, Jonathan G. Leung, Betsy Walters Burkey, Ian R. McGrane, Victoria Letts, Jessica L. Goren, Dawn M. Hoeft, Sandra Mullen, Megan Maroney, Kate D Schak, Jennifer L. Vande Voort

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Objectives: Clozapine is the drug of choice for treatment-resistant schizophrenia. While pediatric clozapine use is not contraindicated, the literature describing its clinical application is limited. The primary objective of this study was to assess the use of clozapine in a child and adolescent population by characterizing the documented safety and clinical benefits of the medication. Methods: A multicenter retrospective study at sites in the United States and Australia included children and adolescents admitted to a psychiatric unit who were administered at least one dose of clozapine. Information related to demographics, patient history, past treatments, clozapine, and adverse events was collected. Results: Eighty-two patients from eight sites were included in this study. Patients were predominantly clozapine naive (76.8%), and most had a discharge diagnosis of a primary psychotic disorder (61%) or bipolar disorder (25.6%). Four clozapine discontinuations occurred during hospitalization due to severe neutropenia, ileus, need for diagnostic clarification, and significant psychomotor retardation. The remainder (n = 78) were discharged on a mean clozapine dose of 218.1 ± 142.2 mg. Sedation (26.8%) and sialorrhea (17.1%) were the most common documented adverse events. The mean number of previously trialed antipsychotics before clozapine was 3.5 ± 1.4 (range 1-10). Improvement with clozapine was documented as significant (31.7%), moderate (32.9%), minimal (12.2%), no improvement (2.4%), and not described (20.7%). Conclusions: In this cohort, 95% of pediatric patients admitted with or started on clozapine during an acute psychiatric hospitalization were discharged on the medication. The high incidence of adverse events should reinforce to clinicians the need for vigilant monitoring. Pediatric guidelines recommend clozapine for refractory schizophrenia but stress the critical need to ensure an accurate diagnosis. Limited data exist for the use of clozapine in pediatric patients with other diagnoses.

Original languageEnglish (US)
Pages (from-to)615-619
Number of pages5
JournalJournal of Child and Adolescent Psychopharmacology
Volume28
Issue number9
DOIs
StatePublished - Nov 1 2018

Keywords

  • bipolar disorder
  • clozapine
  • early-onset schizophrenia
  • pediatric
  • schizophrenia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A retrospective multicenter evaluation of clozapine use in pediatric patients admitted for acute psychiatric hospitalization'. Together they form a unique fingerprint.

  • Cite this

    Steinauer, L. M., Leung, J. G., Burkey, B. W., McGrane, I. R., Letts, V., Goren, J. L., Hoeft, D. M., Mullen, S., Maroney, M., Schak, K. D., & Vande Voort, J. L. (2018). A retrospective multicenter evaluation of clozapine use in pediatric patients admitted for acute psychiatric hospitalization. Journal of Child and Adolescent Psychopharmacology, 28(9), 615-619. https://doi.org/10.1089/cap.2018.0036